Papers
6
Total Citations
107
H-Index
3
About
Dan Garwood is a radiation oncologist whose pioneering work has reshaped early-stage breast cancer treatment through stereotactic body radiation therapy (SBRT) for partial-breast irradiation (PBI). His major contributions center on developing and refining a five-fraction SBRT regimen delivered after lumpectomy, dramatically compressing traditional treatment timelines while maintaining safety and efficacy. Garwood led a landmark Phase 1 dose-escalation trial (2017, 66 citations) that established the feasibility of this approach, systematically testing escalating doses to optimize tumor control and minimize toxicity. He further advanced the field by introducing a novel ultrasound-guided technique for placing gold fiducial markers (2016, 16 citations), enabling precise robotic targeting of the lumpectomy cavity. His subsequent work on cosmetic outcomes (2021, 19 citations) demonstrated that patients maintained excellent breast aesthetics after treatment, addressing a critical quality-of-life concern. By proving that high-dose, hypofractionated partial-breast irradiation could be delivered safely with outstanding cosmetic results, Garwood has helped shift clinical practice toward shorter, more convenient radiation schedules for women with early-stage breast cancer—a contribution with lasting impact on both treatment efficacy and patient experience.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6